AU2012238374B2 - Isoxazole derivatives useful as antibacterial agents - Google Patents

Isoxazole derivatives useful as antibacterial agents Download PDF

Info

Publication number
AU2012238374B2
AU2012238374B2 AU2012238374A AU2012238374A AU2012238374B2 AU 2012238374 B2 AU2012238374 B2 AU 2012238374B2 AU 2012238374 A AU2012238374 A AU 2012238374A AU 2012238374 A AU2012238374 A AU 2012238374A AU 2012238374 B2 AU2012238374 B2 AU 2012238374B2
Authority
AU
Australia
Prior art keywords
methyl
alkyl
isoxazol
hydroxy
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012238374A
Other languages
English (en)
Other versions
AU2012238374A1 (en
Inventor
Joseph A. Abramite
Matthew F. Brown
Jinshan Michael Chen
Michael Melnick
Justin I. MONTGOMERY
Usa Reilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2012238374A1 publication Critical patent/AU2012238374A1/en
Application granted granted Critical
Publication of AU2012238374B2 publication Critical patent/AU2012238374B2/en
Priority to AU2015203690A priority Critical patent/AU2015203690A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012238374A 2011-04-08 2012-03-23 Isoxazole derivatives useful as antibacterial agents Ceased AU2012238374B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015203690A AU2015203690A1 (en) 2011-04-08 2015-07-01 Isoxazole derivatives useful as antibacterial agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473540P 2011-04-08 2011-04-08
US61/473,540 2011-04-08
PCT/IB2012/051406 WO2012137094A1 (en) 2011-04-08 2012-03-23 Isoxazole derivatives useful as antibacterial agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015203690A Division AU2015203690A1 (en) 2011-04-08 2015-07-01 Isoxazole derivatives useful as antibacterial agents

Publications (2)

Publication Number Publication Date
AU2012238374A1 AU2012238374A1 (en) 2013-09-26
AU2012238374B2 true AU2012238374B2 (en) 2015-04-02

Family

ID=45999906

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012238374A Ceased AU2012238374B2 (en) 2011-04-08 2012-03-23 Isoxazole derivatives useful as antibacterial agents

Country Status (14)

Country Link
US (1) US8748466B2 (enExample)
EP (1) EP2694488B1 (enExample)
JP (1) JP2014510132A (enExample)
KR (1) KR20130140868A (enExample)
CN (1) CN103717582B (enExample)
AU (1) AU2012238374B2 (enExample)
CA (1) CA2830920C (enExample)
DK (1) DK2694488T3 (enExample)
ES (1) ES2526687T3 (enExample)
IL (2) IL228799A (enExample)
MX (1) MX2013011526A (enExample)
SG (1) SG193367A1 (enExample)
WO (1) WO2012137094A1 (enExample)
ZA (1) ZA201306736B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722686B2 (en) 2008-09-19 2014-05-13 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
JP5793766B2 (ja) 2009-12-16 2015-10-14 ファイザー・インク 抗菌剤として有用なｎ−結合型ヒドロキサム酸誘導体
AP3336A (en) 2011-03-07 2015-07-31 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
WO2012137099A1 (en) * 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
US9937156B2 (en) * 2013-10-16 2018-04-10 The Board Of Regents Of The University Of Texas System Modulation of MRTF-A activity in pathologic fibrosis and wound healing
KR20160098503A (ko) 2013-12-19 2016-08-18 액테리온 파마슈티칼 리미티드 항균성 1h-인다졸 및 1h-인돌 유도체
AR099612A1 (es) * 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
CN106573924B (zh) * 2014-04-22 2019-06-25 诺华股份有限公司 作为LpxC抑制剂的异噁唑啉异羟肟酸衍生物
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
BR112017010474A2 (pt) 2014-11-19 2017-12-26 Actelion Pharmaceuticals Ltd derivados antibacterianos de benzotiazol
HUE047225T2 (hu) * 2014-12-16 2020-04-28 Novartis Ag LpxC inhibitor izoxazol hidroxámsav-vegyületek
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105848A1 (es) * 2015-08-31 2017-11-15 Actelion Pharmaceuticals Ltd Derivados heterocíclicos antibacterianos
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
US10590498B2 (en) * 2016-05-17 2020-03-17 Lawrence Livermore National Security, Llc Compounds for reactivation of acetylcholinesterase and related compositions methods and systems
SMT202000524T1 (it) 2016-06-14 2020-11-10 Novartis Ag Forma cristallina di (r)-4-(5-(ciclopropiletinil)isossazol-3-il)-n-idrossi-2-metil-2-(metilsolfonil)butanammide come agente antibatterico
DE102016113269A1 (de) 2016-07-19 2018-01-25 Osram Opto Semiconductors Gmbh Leuchtvorrichtung für ein mobiles endgerät
TWI604678B (zh) * 2016-09-07 2017-11-01 國立暨南國際大學 Radio transmission system
AU2017337946B2 (en) * 2016-09-28 2020-05-07 Dong-A St Co., Ltd. Tetrahydropyridine derivatives and their use as antibacterial agents
US11186548B2 (en) 2017-11-23 2021-11-30 Lawrence Livermore National Security, Llc Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them
BR112021009536A2 (pt) * 2018-11-21 2021-08-17 Taisho Pharmaceutical Co., Ltd. derivado de imidazol
CN111944719B (zh) * 2020-08-14 2022-04-29 暨南大学 一株二恶烷降解菌is20及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032147A2 (en) * 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769461A (en) 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US5110831A (en) 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
PL194240B1 (pl) 1998-02-07 2007-05-31 British Biotech Pharm Zastosowanie pochodnych N-formylohydroksyloaminy i amidowa pochodna N-formylohydroksyloaminy
GB9925470D0 (en) 1999-10-27 1999-12-29 Smithkline Beecham Plc Novel compounds
WO2002074298A1 (en) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
ES2180456B1 (es) * 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
ES2387803T3 (es) 2003-01-08 2012-10-02 Novartis Vaccines And Diagnostics, Inc. Agentes antibacterianos
GB0302431D0 (en) 2003-01-30 2003-03-05 Glaxo Group Ltd Novel compounds
EP1828145A4 (en) 2004-12-10 2009-08-19 Univ Emory 2'- AND 3'-SUBSTITUTED CYCLOBUTYL NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRAL INFECTIONS AND ANORMAL CELL PROLIFERATION
WO2006118155A1 (ja) 2005-04-27 2006-11-09 Ishihara Sangyo Kaisha, Ltd. ビフェニル誘導体又はその塩、並びにそれらを有効成分として含有する農園芸用殺菌剤
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
JP2009520695A (ja) 2005-12-15 2009-05-28 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
ES2331930T3 (es) * 2006-02-14 2010-01-20 Pfizer Products Inc. Oxazolidinonas con benzoxazinonas y benzoxazepinonas como agentes antibacterianos.
WO2008045671A1 (en) 2006-10-06 2008-04-17 Janssen Pharmaceutica, N.V. Matrix metalloprotease inhibitors
CN101016270B (zh) * 2006-12-30 2012-05-09 天津药物研究院 取代的哌嗪基苯基异噁唑啉衍生物及其用途
US7879911B2 (en) 2007-02-01 2011-02-01 Johnson Alan T Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
WO2008105515A1 (ja) 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
WO2010017060A1 (en) 2008-08-04 2010-02-11 Schering Corporation Urea derivatives as antibacterial agents
WO2010024356A1 (ja) 2008-08-27 2010-03-04 大正製薬株式会社 ナフチリジン－ｎ－オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
JP5793766B2 (ja) 2009-12-16 2015-10-14 ファイザー・インク 抗菌剤として有用なｎ−結合型ヒドロキサム酸誘導体
AP3336A (en) 2011-03-07 2015-07-31 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
WO2012137099A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032147A2 (en) * 2008-09-19 2010-03-25 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents

Also Published As

Publication number Publication date
IL228799A (en) 2015-08-31
US20140024690A1 (en) 2014-01-23
IL228799A0 (en) 2013-12-31
WO2012137094A1 (en) 2012-10-11
CN103717582B (zh) 2015-09-30
SG193367A1 (en) 2013-10-30
DK2694488T3 (en) 2014-12-15
ZA201306736B (en) 2014-11-26
ES2526687T3 (es) 2015-01-14
CA2830920A1 (en) 2012-10-11
CA2830920C (en) 2015-07-14
KR20130140868A (ko) 2013-12-24
JP2014510132A (ja) 2014-04-24
MX2013011526A (es) 2013-12-06
IL240078A0 (en) 2015-08-31
EP2694488A1 (en) 2014-02-12
EP2694488B1 (en) 2014-11-12
US8748466B2 (en) 2014-06-10
CN103717582A (zh) 2014-04-09
AU2012238374A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
CA2830920C (en) Isoxazole derivatives useful as antibacterial agents
US8809333B2 (en) Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
AU2017263361B2 (en) Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors
CA2176255C (en) Isoxazoline compounds as antiinflammatory agents
CA2744756C (en) Monocarbams and their use as antibacterial agent
US12103904B2 (en) Benzoylglycine derivatives and methods of making and using same
CN111094255A (zh) 具有环状结构的化合物
AU2015203690A1 (en) Isoxazole derivatives useful as antibacterial agents
HK1194368A (en) Isoxazole derivatives useful as antibacterial agents
RU2795119C2 (ru) Соединение, обладающее циклической структурой
AU2015203287A1 (en) Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
HK40104425A (en) Benzoylglycine derivatives and methods of making and using same
HK1190155A (en) Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
BR112019006129B1 (pt) Derivados de tetra-hidropiridina e seu uso como agentes antibacterianos

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired